A comparison of oral Terbinafine and Itraconazole in stubborn Tinea infections
Phase 4
- Conditions
- Health Condition 1: B356- Tinea cruris
- Registration Number
- CTRI/2019/07/019964
- Lead Sponsor
- Dr Vasudha Sharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients with recalcitrant Tinea Cruris
2. Patients willing to give informed consent and comply with the treatment and follow up
Exclusion Criteria
1. <18 years and > 65 years age
2. Pregnant or Lactating women
3. Secondary bacterial infections
4. Deep mycosis
5. Immunocompromised patients- Severe uncontrolled Diabetes, HIV/AIDS, chronic glucocorticoid therapy
6. Patients with abnormal liver function and kidney function test
7. Present or past history of malignancy
8. Patients with known history of allergy to Itraconazole or Terbinafine or related drugs
9. patients with history of ischemic heart disease
10. Patients not giving informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare safety and efficacy of Itraconazole and Terbinafine in achieving complete cure in recalcitrant tinea cruris infections by 4 point rating scaleTimepoint: 2,4,6,8,10,12 weeks
- Secondary Outcome Measures
Name Time Method Compare adverse effect profile of Itraconazole and TerbinafineTimepoint: 2,4,6,8,10,12 weeks;To assess the non-responders, if anyTimepoint: 12 weeks